GLP-1 drug denied: Ozempic, Wegovy, Mounjaro or Zepbound
Short answer: First find out which kind of no you got. If your plan covers the drug but says you didn't meet its criteria (prior authorization, step therapy, BMI or diagnosis), ask for the written criteria and have your prescriber send the records that meet them. If your plan excludes weight-loss drugs, an appeal usually has to show a different covered use, such as diabetes, heart disease risk or sleep apnea. On Medicare, Part D can't cover drugs used for weight loss, but a CMS program called the Medicare GLP-1 Bridge covers some of them for $50 a month from July 1, 2026 through December 31, 2027.
Step 1: Find out which kind of “no” it is
GLP-1 denials fall into three groups, and each needs a different response:
- Criteria not met. The plan covers the drug but wants proof first: prior authorization, trying another drug first (step therapy), a certain diagnosis, or weight and BMI records. This is usually fixable with documentation.
- Not on the formulary. The drug isn't on the plan's list. You can ask for an exception. How drug exceptions work.
- Excluded benefit. The plan doesn't cover drugs for weight loss at all. An appeal arguing you need to lose weight usually won't change that. What can work is showing the drug is prescribed for a different, covered condition.
Read the denial for the exact wording, or call and ask: “Is this drug excluded, or did I not meet the criteria? Please send me the criteria you used.” Job-based plans have to tell you the specific reason, the plan provision they relied on, and what information would complete the claim. They also have to give you, free on request, any internal rule or guideline they used and the documents relevant to your claim.
Step 2: Match the drug to its FDA-approved use
Plans often cover these drugs for some uses and not others, so the diagnosis on the prescription matters. Here's what the FDA has approved each one for:
- Ozempic (semaglutide): blood sugar control in adults with type 2 diabetes; lowering the risk of major heart events in adults with type 2 diabetes and heart disease; and lowering the risk of kidney decline, kidney failure and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. It is not approved for weight loss.
- Wegovy (semaglutide): long-term weight management in adults and children 12 and older with obesity, and adults with overweight plus at least one weight-related condition; lowering the risk of heart attack, stroke and cardiovascular death in adults with heart disease and obesity or overweight; and, in adults, a serious liver disease called MASH (without cirrhosis) with moderate to advanced scarring.
- Mounjaro (tirzepatide): blood sugar control in adults and children 10 and older with type 2 diabetes.
- Zepbound (tirzepatide): long-term weight management in adults with obesity, or overweight plus at least one weight-related condition; and moderate to severe obstructive sleep apnea in adults with obesity.
If you have one of these other conditions, make sure your prescriber's request and records say so. A request for Zepbound for sleep apnea, or Wegovy for heart disease risk, can be treated differently from a request for weight loss.
Job-based and Marketplace plans
Coverage for weight loss is far from universal. In KFF's 2026 survey of employers, 18% of firms with 200 or more workers that offer health benefits covered GLP-1s for weight loss. Among those that did, 40% required people to meet with a dietitian, case manager or therapist, or join a lifestyle program. In KFF's look at 2024 HealthCare.gov plans, Wegovy was covered by just 1% of plans' drug lists, and all of the plans that covered GLP-1s approved for obesity required prior authorization.
What to do:
- Get the criteria. Ask for the written prior authorization or coverage policy for the drug, then go through it line by line with your prescriber.
- Send the missing pieces. Common ones: your diagnosis, height, weight and BMI history, related conditions, other drugs you've tried and what happened, and proof of any required lifestyle program.
- If the drug isn't on the list, plans that must cover essential health benefits (most individual and small-group plans, including Marketplace plans) have to offer an exception process. A standard request is decided within 72 hours, or 24 hours when your health is seriously at risk, and if it's denied you can ask for an independent review.
- Appeal in writing if the answer is still no. For job-based and Marketplace plans you generally have at least 180 days. Check your deadline. Denials based on medical judgment can then go to external review.
Medicare: what Part D can and can't cover
By law, Medicare drug plans (Part D) can't cover drugs when they're used for weight loss, even for obesity. That rule is about the use, not the drug. Part D plans must keep covering GLP-1 drugs for uses Medicare can cover, such as type 2 diabetes, Zepbound for moderate to severe sleep apnea in adults with obesity, and Wegovy to lower heart attack and stroke risk in adults with heart disease and obesity or overweight. For those uses, plans follow their normal rules, including prior authorization, and their normal formulary exception process. If your plan denies one of these, ask for a coverage determination and appeal: how Medicare drug exceptions and appeals work.
The Medicare GLP-1 Bridge (July 2026 to December 2027)
The Medicare GLP-1 Bridge is a short-term CMS program that runs from July 1, 2026 through December 31, 2027. It runs outside the regular Part D benefit. According to Medicare.gov:
- Drugs: Foundayo tablets, Wegovy injections or tablets, and Zepbound KwikPen. Single-dose Zepbound vials or pens aren't covered.
- Cost: a $50 copayment for a one-month supply. It doesn't count toward your Part D deductible or out-of-pocket limit.
- Who qualifies: adults 18 and older with a BMI of 35 or higher; or a BMI of 30 or higher with diastolic heart failure, uncontrolled high blood pressure, or chronic kidney disease stage 3a or higher; or a BMI of 27 or higher with prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease.
- Who doesn't: people already getting a GLP-1 through Part D, and people with type 2 diabetes, moderate to severe sleep apnea, or fatty liver disease. For those conditions, Medicare says your Part D plan might cover your GLP-1.
- Paperwork: your provider must certify that you're using the drug as part of a lifestyle program. An approval lasts through December 31, 2027, including refills and dose changes, unless you switch to a different GLP-1 drug.
CMS says the Bridge doesn't change your Part D appeal rights. Medicare.gov doesn't describe a separate appeal process for the Bridge, so if a Bridge request is turned down, call 1-800-MEDICARE and ask what to do next. What happens after 2027 hasn't been announced; CMS has delayed a planned longer-term program called BALANCE, which had been set to start in Part D in January 2027. Free one-on-one help is available from your State Health Insurance Assistance Program (SHIP).
Medicaid
State Medicaid programs choose whether to cover drugs for weight loss, but they must cover drugs approved for diabetes. KFF counted 13 state Medicaid programs covering GLP-1s for obesity under fee-for-service as of January 2026, and coverage usually comes with prior authorization. Check your state's preferred drug list, and if you're denied, appeal through Medicaid.
What your prescriber's request should include
- The diagnosis the drug is being prescribed for, matching an FDA-approved use.
- Your weight, height and BMI history, with dates.
- Related conditions, such as heart disease, sleep apnea, prediabetes or kidney disease, with the records that show them.
- Drugs you've already tried, the dates, and why they didn't work or weren't safe for you.
- Any lifestyle, nutrition or exercise program you're part of.
- Whether stopping or delaying the drug could seriously harm your health. If so, ask for an expedited decision.
Compounded and cash-price options
The FDA declared the shortages of tirzepatide injection (first on October 2, 2024, confirmed December 19, 2024) and semaglutide injection (February 21, 2025) resolved. The FDA notes that compounded drugs are not FDA-approved. If you pay cash through a discount program such as TrumpRx, KFF notes those payments don't count toward your insurance deductible or out-of-pocket maximum.
Your next question
Prescription drug denied: how to ask for an exceptionYour plan won't cover a drug, or wants you to try a cheaper one first? Ask for an exception. Many plans must…Denied because prior authorization wasn't obtainedA CO-197 'no prior authorization' denial is often winnable. Emergency care generally needs no prior…How to appeal a Medicare Advantage denialMedicare Advantage gives you 65 days to ask for a reconsideration. Here's how to file, how fast the plan must… Check your appeal deadlinePick your plan type and the date on your letter. Free, and nothing is sent anywhere.Common questions
Why was Ozempic approved for my friend but denied for me?
Ozempic is FDA-approved for type 2 diabetes and related heart and kidney risk, not for weight loss. Plans often cover it only with a type 2 diabetes diagnosis. Wegovy and Zepbound are the versions approved for weight management, and many plans exclude or restrict them.
Does Medicare cover Wegovy or Zepbound?
Part D can't cover drugs used for weight loss, but it can cover Wegovy to lower heart attack and stroke risk in adults with heart disease and obesity or overweight, and Zepbound for moderate to severe sleep apnea. From July 1, 2026 through December 31, 2027, the Medicare GLP-1 Bridge covers Wegovy, Zepbound KwikPen and Foundayo for eligible people for a $50 monthly copay.
Can I appeal if my plan excludes weight-loss drugs?
You can always appeal, but an exclusion is hard to overturn by arguing you need to lose weight. Ask whether the drug could be covered for another FDA-approved use you have, such as diabetes, heart disease risk or sleep apnea, and have your prescriber document it.
Let the app write it for you
Snap a photo of your denial letter. Appeal My Denial tells you why you were denied, your exact deadline, and drafts the appeal letter, plus the note for your doctor.
Coming soon to the App StoreSources
- FDA: Ozempic (semaglutide) prescribing information (rev. 10/2025)
- FDA: Wegovy (semaglutide) prescribing information (rev. 08/2025)
- FDA: Mounjaro (tirzepatide) prescribing information (rev. 01/2026)
- FDA: Zepbound (tirzepatide) prescribing information (rev. 04/2026)
- 29 CFR 2560.503-1 (ERISA claims procedure, eCFR)
- 45 CFR 156.122 (prescription drug benefits and the exceptions process)
- HealthCare.gov: Internal appeals
- KFF: 2026 Employer Health Benefits Survey
- KFF: Costly GLP-1 Drugs Are Rarely Covered for Weight Loss by Marketplace Plans (June 2024)
- CMS: Medicare Prescription Drug Benefit Manual, Chapter 6 (Part D drugs and formulary requirements)
- CMS: Medicare GLP-1 Bridge — Expectations and FAQs for Part D Sponsors (June 2026)
- CMS: Medicare GLP-1 Bridge
- Medicare.gov: Weight-loss drugs
- KFF: CMS Extends Medicare’s Short-Term Bridge Program for GLP-1 Obesity Drug Coverage (Apr 2026)
- KFF: Medicaid Coverage of and Spending on GLP-1s (Jan 2026)
- FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
- KFF: TrumpRx — What’s the Value for Customers? (Feb 2026)
- SHIP: State Health Insurance Assistance Programs (free Medicare counseling)